Biohaven Pharmaceutical Holding Company Ltd. (BHVN) posted a quarterly loss of $3.01 per share against Zacks consensus estimate of a loss of $2.07. That compares to a loss of $3.62 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents a profit surprise of -45.41%. A quarter ago, this company was expected to post a loss of $2.44 per share when it actually produced a loss of $2.63, delivering a surprise of -7.79% .
Over the past four quarters, the company has been unable to exceed consensus EPS estimates.
Biohaven Pharmaceutical Holding Company Ltd.
The sustainability of the immediate stock price movement based on recently released numbers and future earnings forecasts will primarily depend on management’s comments on the earnings call.
The shares of Biohaven Pharmaceutical Holding Company Ltd. have lost around 2.9% since the start of the year compared to the -10% decline in the S&P 500.
What’s next for Biohaven Pharmaceutical Holding Company Ltd.
While Biohaven Pharmaceutical Holding Company Ltd. has outperformed the market so far this year, the question on investors’ minds is: what’s next for the stock?
There are no easy answers to this key question, but one reliable metric that can help investors answer it is the company’s earnings outlook. This includes not only current consensus earnings expectations for the upcoming quarter(s), but also how those expectations have changed recently.
Empirical research shows a strong correlation between short-term stock movements and trends in earnings estimate revisions. Investors can track these revisions on their own or rely on a proven scoring tool like Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Before that Press release, the trend of estimate revisions for Biohaven Pharmaceutical Holding Company Ltd. Mixed. While the magnitude and direction of estimate revisions may change following the release of the company’s earnings report, the current situation translates into a No. 3 (hold) Zacks ranking for the stock. Thus, the shares should move in line with the market in the near future. You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how the estimates for the next few quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.53 on $187.4 million in revenue for the upcoming quarter and -$6.05 on $933.03 million in revenue for the current fiscal year .
Investors should be aware that the outlook for the sector can also have a significant impact on stock performance. In terms of Zacks industry rankings, the medical – biomedical and genetics sector currently sits in the bottom 41% of the more than 250 Zacks industries. Our research shows that the top 50% of industries ranked by Zacks outperform the bottom 50% by a factor of more than 2 to 1.
Another stock in the same sector, Leap Therapeutics, Inc. (LPTX), has yet to report results for the quarter ended December 2021.
This company is expected to post a quarterly loss of $0.11 per share in its next report, representing a year-over-year change of -22.2%. The consensus EPS estimate for the quarter remained unchanged for the past 30 days.
Leap Therapeutics, Inc. revenue is expected to be $0.38 million, unchanged from the prior year quarter.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know our top 10 picks for all of 2022?
From its creation in 2012 to 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% vs. +348.7% for the S&P 500. Now our research director has combed through 4,000 companies covered by the Zacks Ranking and selected the top 10 tickers to buy and keep. Don’t miss your chance to enter…because the sooner you do, the better your chances of winning.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.